Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Mustafa Khasraw, MBChB, MD, FRCP, FRACP sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).
Mustafa Khasraw, MBChB, MD, FRCP, FRACP: 4 sponsored US clinical trials, none currently recruiting.
Mustafa Khasraw, MBChB, MD, FRCP, FRACP sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 1 completed. 0 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Glioma, Malignant, with 1 trials.
Upper-quartile sponsor footprint
Mustafa Khasraw, MBChB, MD, FRCP, FRACP sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.
Indexed trials (enrollment closed)
4 total, page 1 of 1
ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM
NCT05283109
BRiTE - Bispecific T Cell Engager for Patients With Glioblastoma
NCT04903795
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
NCT03927222
DC Migration Study for Newly-Diagnosed GBM
NCT02366728
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 2 |
Therapeutic Areas
How the Mustafa Khasraw, MBChB, MD, FRCP, FRACP early-phase archive is shaped
4 indexed studies, none listed as recruiting (0% open); 1 completed (25%).
Phase mix: 0 late (III/IV) vs 4 early (I/II) (early-phase heavy).
Top condition: Glioma, Malignant (1 trial), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Mustafa Khasraw, MBChB, MD, FRCP, FRACP: archived-pipeline peers nationwide
Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Mustafa Khasraw, MBChB, MD, FRCP, FRACP sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 4 archived trials
- 4D pharma · 4 trials · 0% recruiting
- 60 Degrees Pharmaceuticals · 4 trials · 50% recruiting
- A2 Biotherapeutics · 4 trials · 75% recruiting
- Abdul Latif Jameel Poverty Action Lab · 4 trials · 25% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Mustafa Khasraw, MBChB, MD, FRCP, FRACP page
4 registered trials is a research-attention snapshot, not an endorsement of Mustafa Khasraw, MBChB, MD, FRCP, FRACP or any single study.
- None of Mustafa Khasraw, MBChB, MD, FRCP, FRACP's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Glioma, Malignant is the condition Mustafa Khasraw, MBChB, MD, FRCP, FRACP studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Glioma, Malignant trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Mustafa Khasraw, MBChB, MD, FRCP, FRACP pipeline card: 4 registered trials from official public datasets.Report a data error.